Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Nang Kuang Pharmaceutical

GTSM:1752
Snowflake Description

Flawless balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1752
GTSM
NT$4B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

Nang Kuang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in Taiwan. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
  • Nang Kuang Pharmaceutical has significant price volatility in the past 3 months.
1752 Share Price and Events
7 Day Returns
16.5%
GTSM:1752
11.1%
TW Pharmaceuticals
5.2%
TW Market
1 Year Returns
36.2%
GTSM:1752
-24.7%
TW Pharmaceuticals
-9.9%
TW Market
1752 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Nang Kuang Pharmaceutical (1752) 16.5% -3.3% -2.3% 36.2% -2.3% -5.4%
TW Pharmaceuticals 11.1% -18.4% -21.6% -24.7% -31.8% -32.8%
TW Market 5.2% -14.4% -19.7% -9.9% -3.3% -0.2%
1 Year Return vs Industry and Market
  • 1752 outperformed the Pharmaceuticals industry which returned -24.7% over the past year.
  • 1752 outperformed the Market in Taiwan, Province of China which returned -9.9% over the past year.
Price Volatility
1752
Industry
5yr Volatility vs Market

Value

 Is Nang Kuang Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Nang Kuang Pharmaceutical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Nang Kuang Pharmaceutical.

GTSM:1752 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.9%
Perpetual Growth Rate 10-Year TW Government Bond Rate 0.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:1752
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 0.7%
Equity Risk Premium S&P Global 6.2%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.69 (1 + (1- 20%) (11.49%))
0.835
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.84
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.71% + (0.835 * 6.21%)
5.9%

Discounted Cash Flow Calculation for GTSM:1752 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Nang Kuang Pharmaceutical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

GTSM:1752 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (TWD, Millions) Source Present Value
Discounted (@ 5.9%)
2020 224.22 Est @ 0.07% 211.73
2021 224.80 Est @ 0.26% 200.46
2022 225.69 Est @ 0.39% 190.05
2023 226.79 Est @ 0.49% 180.35
2024 228.05 Est @ 0.56% 171.25
2025 229.42 Est @ 0.6% 162.69
2026 230.88 Est @ 0.63% 154.61
2027 232.39 Est @ 0.66% 146.96
2028 233.96 Est @ 0.67% 139.71
2029 235.56 Est @ 0.68% 132.83
Present value of next 10 years cash flows NT$1,690.00
GTSM:1752 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= NT$235.56 × (1 + 0.71%) ÷ (5.9% – 0.71%)
NT$4,574.57
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= NT$4,574.57 ÷ (1 + 5.9%)10
NT$2,579.65
GTSM:1752 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= NT$1,690.00 + NT$2,579.65
NT$4,269.65
Equity Value per Share
(TWD)
= Total value / Shares Outstanding
= NT$4,269.65 / 100.99
NT$42.28
GTSM:1752 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$42.28
Current discount Discount to share price of NT$41.00
= -1 x (NT$41.00 - NT$42.28) / NT$42.28
3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Nang Kuang Pharmaceutical is available for.
Intrinsic value
3%
Share price is NT$41 vs Future cash flow value of NT$42.28
Current Discount Checks
For Nang Kuang Pharmaceutical to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Nang Kuang Pharmaceutical's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Nang Kuang Pharmaceutical's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Nang Kuang Pharmaceutical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Nang Kuang Pharmaceutical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:1752 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in TWD NT$2.17
GTSM:1752 Share Price ** GTSM (2020-03-30) in TWD NT$41
Taiwan, Province of China Pharmaceuticals Industry PE Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 18.53x
Taiwan, Province of China Market PE Ratio Median Figure of 1,466 Publicly-Listed Companies 13.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Nang Kuang Pharmaceutical.

GTSM:1752 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:1752 Share Price ÷ EPS (both in TWD)

= 41 ÷ 2.17

18.89x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nang Kuang Pharmaceutical is overvalued based on earnings compared to the TW Pharmaceuticals industry average.
  • Nang Kuang Pharmaceutical is overvalued based on earnings compared to the Taiwan, Province of China market.
Price based on expected Growth
Does Nang Kuang Pharmaceutical's expected growth come at a high price?
Raw Data
GTSM:1752 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 18.89x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Taiwan, Province of China Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 0.87x
Taiwan, Province of China Market PEG Ratio Median Figure of 197 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Nang Kuang Pharmaceutical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Nang Kuang Pharmaceutical's assets?
Raw Data
GTSM:1752 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in TWD NT$21.66
GTSM:1752 Share Price * GTSM (2020-03-30) in TWD NT$41
Taiwan, Province of China Pharmaceuticals Industry PB Ratio Median Figure of 45 Publicly-Listed Pharmaceuticals Companies 1.81x
Taiwan, Province of China Market PB Ratio Median Figure of 1,963 Publicly-Listed Companies 1.16x
GTSM:1752 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:1752 Share Price ÷ Book Value per Share (both in TWD)

= 41 ÷ 21.66

1.89x

* Primary Listing of Nang Kuang Pharmaceutical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nang Kuang Pharmaceutical is overvalued based on assets compared to the TW Pharmaceuticals industry average.
X
Value checks
We assess Nang Kuang Pharmaceutical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Nang Kuang Pharmaceutical has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Nang Kuang Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38.3%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Nang Kuang Pharmaceutical expected to grow at an attractive rate?
  • Unable to compare Nang Kuang Pharmaceutical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Nang Kuang Pharmaceutical's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
  • Unable to compare Nang Kuang Pharmaceutical's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:1752 Future Growth Rates Data Sources
Data Point Source Value (per year)
Taiwan, Province of China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 38.3%
Taiwan, Province of China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 15.4%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.3%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:1752 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:1752 Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 1,968 1
2020-03-30
GTSM:1752 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-12-31 1,762 386 217
2019-09-30 1,674 435 161
2019-06-30 1,563 373 110
2019-03-31 1,537 380 99
2018-12-31 1,539 366 101
2018-09-30 1,564 307 129
2018-06-30 1,575 255 153
2018-03-31 1,531 331 158
2017-12-31 1,504 323 186
2017-09-30 1,420 363 203
2017-06-30 1,434 455 211
2017-03-31 1,493 393 225

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Nang Kuang Pharmaceutical is high growth as no earnings estimate data is available.
  • Unable to determine if Nang Kuang Pharmaceutical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:1752 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Nang Kuang Pharmaceutical Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:1752 Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2020-03-30
GTSM:1752 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-12-31 2.17
2019-09-30 1.60
2019-06-30 1.10
2019-03-31 0.98
2018-12-31 1.00
2018-09-30 1.28
2018-06-30 1.52
2018-03-31 1.57
2017-12-31 1.84
2017-09-30 2.01
2017-06-30 2.09
2017-03-31 2.24

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Nang Kuang Pharmaceutical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Nang Kuang Pharmaceutical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Nang Kuang Pharmaceutical has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Nang Kuang Pharmaceutical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Nang Kuang Pharmaceutical's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Nang Kuang Pharmaceutical's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Nang Kuang Pharmaceutical's 1-year earnings growth exceeds its 5-year average (114.8% vs -2%)
  • Nang Kuang Pharmaceutical's earnings growth has exceeded the TW Pharmaceuticals industry average in the past year (114.8% vs 3.6%).
Earnings and Revenue History
Nang Kuang Pharmaceutical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Nang Kuang Pharmaceutical Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:1752 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1,762.26 217.44 244.67 130.77
2019-09-30 1,673.73 160.62 213.54 127.22
2019-06-30 1,562.76 110.10 206.75 135.84
2019-03-31 1,536.75 98.91 215.04 149.41
2018-12-31 1,538.53 101.23 218.03 154.68
2018-09-30 1,564.49 129.15 217.74 173.13
2018-06-30 1,574.51 153.01 229.14 160.81
2018-03-31 1,531.31 158.46 221.77 143.49
2017-12-31 1,503.72 185.82 219.49 135.84
2017-09-30 1,419.51 202.63 225.95 116.12
2017-06-30 1,434.20 210.61 221.77 118.65
2017-03-31 1,493.41 225.09 227.99 116.15
2016-12-31 1,549.71 225.50 229.53 116.40
2016-09-30 1,608.48 212.08 232.66 120.46
2016-06-30 1,600.82 233.23 233.95 113.40
2016-03-31 1,570.51 227.45 232.06 108.84
2015-12-31 1,520.33 198.99 232.04 106.28
2015-09-30 1,468.10 187.90 224.75 95.29
2015-06-30 1,450.62 153.45 220.26 96.13
2015-03-31 1,363.22 109.30 211.99 100.90
2014-12-31 1,276.78 67.28 203.37 114.44
2014-09-30 1,217.54 19.46 200.71 125.27
2014-06-30 1,106.49 -6.52 195.30 118.44
2014-03-31 1,056.45 -14.49 194.60 120.91
2013-12-31 1,012.92 -7.82 193.02 103.95
2013-09-30 970.30 5.34 186.91 90.36
2013-06-30 953.39 26.41 181.56 91.06
2013-03-31 946.48 63.01 174.31 75.97

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Nang Kuang Pharmaceutical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Nang Kuang Pharmaceutical used its assets more efficiently than the TW Pharmaceuticals industry average last year based on Return on Assets.
  • Nang Kuang Pharmaceutical has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Nang Kuang Pharmaceutical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Nang Kuang Pharmaceutical has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Nang Kuang Pharmaceutical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Nang Kuang Pharmaceutical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Nang Kuang Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Nang Kuang Pharmaceutical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Nang Kuang Pharmaceutical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Nang Kuang Pharmaceutical Company Filings, last reported 2 months ago.

GTSM:1752 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 2,187.28 473.99 393.52
2019-09-30 2,070.18 443.97 259.91
2019-06-30 2,009.75 332.99 162.98
2019-03-31 2,088.60 409.97 158.80
2018-12-31 2,053.14 474.99 178.03
2018-09-30 2,059.25 585.34 237.82
2018-06-30 2,049.34 520.30 302.20
2018-03-31 2,180.86 603.08 327.50
2017-12-31 2,143.22 672.90 380.62
2017-09-30 2,095.97 663.96 351.89
2017-06-30 2,062.19 571.93 459.06
2017-03-31 2,188.25 587.96 342.92
2016-12-31 2,123.14 598.93 371.28
2016-09-30 2,049.53 617.95 340.68
2016-06-30 2,001.17 539.53 356.47
2016-03-31 2,061.05 596.03 323.78
2015-12-31 1,994.32 597.23 311.60
2015-09-30 1,770.32 760.79 260.27
2015-06-30 1,533.88 1,019.46 255.16
2015-03-31 1,534.26 1,005.20 268.00
2014-12-31 1,441.40 921.82 250.25
2014-09-30 1,424.16 842.54 177.68
2014-06-30 1,395.70 840.89 180.08
2014-03-31 1,420.65 864.62 140.03
2013-12-31 1,425.59 882.69 170.39
2013-09-30 1,286.62 916.65 119.52
2013-06-30 1,255.07 924.26 121.12
2013-03-31 1,284.60 880.61 100.29
  • Nang Kuang Pharmaceutical's level of debt (21.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (64% vs 21.7% today).
  • Debt is well covered by operating cash flow (81.5%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 4331x coverage).
X
Financial health checks
We assess Nang Kuang Pharmaceutical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Nang Kuang Pharmaceutical has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Nang Kuang Pharmaceutical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
4.15%
Current annual income from Nang Kuang Pharmaceutical dividends.
If you bought NT$2,000 of Nang Kuang Pharmaceutical shares you are expected to receive NT$83 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Nang Kuang Pharmaceutical's pays a higher dividend yield than the bottom 25% of dividend payers in Taiwan, Province of China (3.31%).
  • Nang Kuang Pharmaceutical's dividend is below the markets top 25% of dividend payers in Taiwan, Province of China (7.12%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:1752 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 22 Stocks 3.5%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1332 Stocks 4.6%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.8%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 3.3%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:1752 Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2020-03-30
GTSM:1752 Past Annualized Dividends Data
Date (Data in NT$) Dividend per share (annual) Avg. Yield (%)
2020-03-20 1.700 4.584
2019-04-01 1.200 3.414
2019-03-13 1.200 3.967
2018-03-30 1.600 4.858
2017-03-31 1.600 4.188
2016-03-31 1.200 2.810
2015-03-19 0.500 1.181
2014-08-12 0.000 0.000
2014-05-12 0.000 0.000
2014-03-28 0.280 0.928
2013-05-13 0.267 0.806
2013-03-27 0.267 0.826
2012-03-19 0.178 0.585
2012-01-16 0.178 0.728
2011-10-31 0.000 0.000
2011-10-28 0.000 0.000
2011-08-30 0.000 0.000
2011-07-15 0.000 0.000
2011-04-29 0.000 0.000
2011-04-27 0.000 0.000
2010-04-29 0.178 0.617
2010-04-19 0.178 0.618
2009-04-28 0.890 3.769
2009-04-06 0.890 4.038

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Nang Kuang Pharmaceutical's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.3x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Nang Kuang Pharmaceutical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Nang Kuang Pharmaceutical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Nang Kuang Pharmaceutical has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Nang Kuang Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Nang Kuang Pharmaceutical has no CEO, or we have no data on them.
Management Team
Board of Directors
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Nang Kuang Pharmaceutical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Nang Kuang Pharmaceutical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Nang Kuang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in Taiwan. It offers parenterals, aseptic parenterals, lyophilized injections, pre-filled syringes, and pre-mixed IV infusion bags, as well as tablets, capsules, topical products, and oral suspensions. The company provides various products in the areas of cardiovascular system, gastrointestinal system, nervous system, musculo-skeletal system, respiratory system, alimentary and metabolism, blood, antineoplastic and immunomodulatory, dermatological, genito-urinary and sex hormone, systemic hormone, and systemic antibacterial, as well as hospital solution. Nang Kuang Pharmaceutical Co., Ltd. was founded in 1963 and is headquartered in Tainan, Taiwan.

Details
Name: Nang Kuang Pharmaceutical Co., Ltd.
1752
Exchange: GTSM
Founded: 1963
NT$4,140,549,000
100,989,000
Website: http://www.nangkuang.com.tw
Address: Nang Kuang Pharmaceutical Co., Ltd.
No. 1001, Zhongshan Road,
Xinhua District,
Tainan,
71243,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 1752 Common Stock Taipei Exchange TW TWD 14. Jun 2005
Number of employees
Current staff
Staff numbers
0
Nang Kuang Pharmaceutical employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/30 16:19
End of day share price update: 2020/03/30 00:00
Last estimates confirmation: 2020/03/09
Last earnings filing: 2020/03/20
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.